Companies / Zevra Therapeutics, Inc. / Activity
Activity — Zevra Therapeutics, Inc.
43 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Feb 2, 2026 | McFarlane Neil F. CEO | Sell | Common Stock | $853.4K | -91K -19.98% | 364,350 0.61% of shares | medium |
| Dec 31, 2025 | Clifton R. LaDuane | Other | Common Stock | $434.7K | -49K -25.26% | 143,515 0.24% of shares | low |
| Mar 24, 2026 | Bode John B Director | Exercise | Common Stock | $194.8K | +39K +87.11% | 84,200 0.14% of shares | low |
| Mar 24, 2026 | Bode John B Director | Exercise | Common Stock | $191.7K | +39K +46.56% | 123,400 0.21% of shares | low |
| Feb 9, 2026 | McFarlane Neil F. CEO | Sell | Common Stock | $125.2K | -15K -3.64% | 387,225 0.65% of shares | medium |
| Feb 3, 2026 | Schafer Joshua Executive | Sell | Common Stock | $96.5K | -11K -14.43% | 62,278 0.10% of shares | low |
| Jan 30, 2026 | Quartel Adrian W Executive | Sell | Common Stock | $40.0K | -5K -31.80% | 9,723 0.02% of shares | low |
| Jan 30, 2026 | Thompson Rahsaan Executive | Sell | Common Stock | $36.0K | -4K -7.56% | 49,919 0.08% of shares | low |
| Jan 30, 2026 | Schafer Joshua Executive | Sell | Common Stock | $29.8K | -3K -8.27% | 37,444 0.06% of shares | low |
| Feb 3, 2026 | Sangiovanni Timothy J. Executive | Sell | Common Stock | $27.5K | -3K -9.21% | 29,590 0.05% of shares | low |
| Jan 30, 2026 | Sangiovanni Timothy J. Executive | Sell | Common Stock | $15.4K | -2K -7.72% | 20,924 0.04% of shares | low |
| Dec 31, 2025 | Clifton R. LaDuane | Exercise | Common Stock | $0 | +141K +273.88% | 192,028 0.32% of shares | low |
| Jun 4, 2026 | Favorito Tamara a Director | Grant | Stock Option (right to buy) | — | +30K | 30,000 0.05% of shares | low |
| Jan 30, 2026 | Thompson Rahsaan Executive | Exercise | Restricted Stock Unit | — | -11K -33.33% | 22,667 0.04% of shares | low |
| Jan 29, 2026 | Thompson Rahsaan Executive | Grant | Stock Option (right to buy) | — | +75K | 75,000 0.13% of shares | low |
| Jan 29, 2026 | Thompson Rahsaan Executive | Grant | Restricted Stock Unit | — | +38K | 37,500 0.06% of shares | low |
| Jan 30, 2026 | Thompson Rahsaan Executive | Exercise | Common Stock | — | +11K +26.56% | 53,999 0.09% of shares | low |
| Jan 31, 2026 | Sangiovanni Timothy J. Executive | Exercise | Restricted Stock Unit | — | -12K -50.00% | 11,668 0.02% of shares | low |
| Jan 30, 2026 | Sangiovanni Timothy J. Executive | Exercise | Restricted Stock Unit | — | -6K -33.33% | 12,667 0.02% of shares | low |
| Jan 31, 2026 | Sangiovanni Timothy J. Executive | Exercise | Common Stock | — | +12K +55.75% | 32,590 0.05% of shares | low |
| Jan 30, 2026 | Sangiovanni Timothy J. Executive | Exercise | Common Stock | — | +6K +38.76% | 22,674 0.04% of shares | low |
| Feb 7, 2026 | McFarlane Neil F. CEO | Exercise | Restricted Stock Unit | — | -38K -33.33% | 75,000 0.13% of shares | low |
| Feb 7, 2026 | McFarlane Neil F. CEO | Exercise | Common Stock | — | +38K +10.29% | 401,850 0.68% of shares | low |
| Jan 31, 2026 | McFarlane Neil F. CEO | Exercise | Restricted Stock Unit | — | -233K -50.00% | 233,333 0.39% of shares | low |
| Jan 29, 2026 | McFarlane Neil F. CEO | Grant | Stock Option (right to buy) | — | +250K | 250,000 0.42% of shares | low |
| Jan 29, 2026 | McFarlane Neil F. CEO | Grant | Restricted Stock Unit | — | +125K | 125,000 0.21% of shares | low |
| Jan 31, 2026 | McFarlane Neil F. CEO | Exercise | Common Stock | — | +233K +105.10% | 455,350 0.77% of shares | low |
| Mar 24, 2026 | Bode John B Director | Exercise | Stock Option (right to buy) | — | -39K -100.00% | 0 0.00% of shares | low |
| Mar 24, 2026 | Bode John B Director | Exercise | Stock Option (right to buy) | — | -39K -66.67% | 19,600 0.03% of shares | low |
| Dec 31, 2025 | Clifton R. LaDuane | Exercise | Performance Stock Unit | — | -20K -100.00% | 0 0.00% of shares | low |
| Dec 31, 2025 | Clifton R. LaDuane | Exercise | Restricted Stock Unit | — | -34K -100.00% | 0 0.00% of shares | low |
| Dec 31, 2025 | Clifton R. LaDuane | Exercise | Restricted Stock Unit | — | -87K -100.00% | 0 0.00% of shares | low |
| Mar 18, 2026 | Renz Justin A Executive | Grant | Stock Option (right to buy) | — | +300K | 300,000 0.51% of shares | low |
| Jan 31, 2026 | Schafer Joshua Executive | Exercise | Restricted Stock Unit | — | -35K -50.00% | 35,333 0.06% of shares | low |
| Jan 30, 2026 | Schafer Joshua Executive | Exercise | Restricted Stock Unit | — | -11K -33.33% | 22,667 0.04% of shares | low |
| Jan 29, 2026 | Schafer Joshua Executive | Grant | Stock Option (right to buy) | — | +75K | 75,000 0.13% of shares | low |
| Jan 29, 2026 | Schafer Joshua Executive | Grant | Restricted Stock Unit | — | +38K | 37,500 0.06% of shares | low |
| Jan 31, 2026 | Schafer Joshua Executive | Exercise | Common Stock | — | +35K +94.36% | 72,778 0.12% of shares | low |
| Jan 30, 2026 | Schafer Joshua Executive | Exercise | Common Stock | — | +11K +38.44% | 40,819 0.07% of shares | low |
| Jan 30, 2026 | Quartel Adrian W Executive | Exercise | Restricted Stock Unit | — | -11K -33.33% | 22,667 0.04% of shares | low |
| Jan 29, 2026 | Quartel Adrian W Executive | Grant | Stock Option (right to buy) | — | +75K | 75,000 0.13% of shares | low |
| Jan 29, 2026 | Quartel Adrian W Executive | Grant | Restricted Stock Unit | — | +38K | 37,500 0.06% of shares | low |
| Jan 30, 2026 | Quartel Adrian W Executive | Exercise | Common Stock | — | +11K +387.72% | 14,256 0.02% of shares | low |